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Constipation and fecal incontinence (FI) are common complaints predominantly affecting
the elderly and women. They are associated with significant morbidity and high health-
care costs. The causes are often multi-factorial and overlapping. With the advent of new
technologies, we have a better understanding of their underlying pathophysiology which
may involve disruption at any levels along the gut–brain–microbiota axis. Initial approach to
management should always be the exclusion of secondary causes. Mild symptoms can be
approached with conservative measures that may include dietary modifications, exercise,
and medications. New prokinetics (e.g., prucalopride) and secretagogues (e.g., lubipros-
tone and linaclotide) are effective and safe in constipation. Biofeedback is the treatment
of choice for dyssynergic defecation. Refractory constipation may respond to neuromod-
ulation therapy with colectomy as the last resort especially for slow-transit constipation
of neuropathic origin. Likewise, in refractory FI, less invasive approach can be tried first
before progressing to more invasive surgical approach. Injectable bulking agents, sacral
nerve stimulation, and SECCA procedure have modest efficacy but safe and less invasive.
Surgery has equivocal efficacy but there are promising new techniques including dynamic
graciloplasty, artificial bowel sphincter, and magnetic anal sphincter. Despite being challeng-
ing, there are no short of alternatives in our toolbox for the management of constipation
and FI.
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INTRODUCTION
Both constipation and fecal incontinence (FI) are common symp-
toms facing primary care physicians and gastroenterologists alike.
Predominantly affecting the elderly and women (1, 2), these symp-
toms are associated with significant morbidity, impaired quality of
life, and associated with high health expenditures (3, 4). Consti-
pation can be broadly classified as functional constipation (FC),
dyssynergic defecation (DD), and constipation-predominant irri-
table bowel syndrome (IBS-C). These sub-categories are defined
according to the Rome III criteria (5, 6). It must be noted that these
sub-categories are not mutually exclusive and evidence suggest that
overlap frequently exists. FI is involuntary loss of rectal contents
(including liquid or solid stool or gas) and can be subcategorized
into passive incontinence (loss of stool without the urge to defe-
cate), urge incontinence (inability to postpone defecation urge),
and fecal seepage (involuntary loss of small amounts of stool) (7).
Constipation affects between 2 and 28% of adults (8) with com-
parable figures in children but mainly affecting boys rather than
girls (9, 10). FI affects approximately 8.3% of non-institutionalized
adults (11) and at least 30% of residents in nursing homes (12).
These figures are likely to be underestimated because of several
barriers, including misconceptions, embarrassment, and social
stigma. With a growing aging population world-wide, it is expected
that both conditions will be seeing an upward trend in the future.
The underlying pathophysiology has not been fully understood
and treatment options remain limited in refractory cases. With
advent of new technologies and molecular techniques, there are
steady strides in the understanding of their pathophysiology as
well as treatment options. The current review aims to provide an
update on the pathophysiology and current management options
of these two common conditions.
CONSTIPATION
PATHOPHYSIOLOGY
The colon serves as a conduit for transporting formed stools into
the anorectum for evacuation when socially acceptable. The func-
tions are coordinated through neurotransmitters (acetylcholine,
nitric oxide, serotonin, calcitonin gene-related peptide), colonic
reflexes, learned behaviors, and gut microbiota. These functions
can be disrupted at any levels along the gut–brain–microbiota axis.
Neuropathy or myopathy can result in slow-transit constipation
(Figure 1), which may be localized or is part of a more general-
ized form of dysmotility and pseudo-obstruction syndrome. With
colonic manometry, the phasic motor activity may exhibit signif-
icant impairment in response to a meal (13) and upon waking
in the morning. The periodic rectal motor activity (PRMA) may
be increased (14) and this will retard colonic propulsion. There
is some evidence for hormonal involvement which may explain
the female predominance (15). Of interest, methanogenic flora
has been found to be significantly associated with constipation
(16, 17) and its elimination with antibiotics has been shown to
improve symptoms (18).
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FIGURE 1 | Colonic manometry tracings in response to a meal.Traces for normal, neuropathy, and myopathy changes in slow-transit constipation are shown.
On the other hand, DD is often an acquired form of behav-
ioral disorder in adulthood and a third arises during childhood
(19). The paradoxical anal contraction during bearing down is
a result of poor rectoanal muscles coordination (Figure 2). Rec-
tal hyposensitivity and abnormal rectal compliance are frequently
associated with DD (20) and their improvement with biofeedback
suggests they are consequences rather than causative (21). More
recently, puborectalis muscle has been shown to play an important
role in preserving fecal continence (22) and also in sensorimotor
response that coincides with the desire to defecate (23).
The pathophysiology of IBS-C is more complex and data sug-
gest it is almost indistinguishable from FC since abdominal pain
is not exclusive to IBS-C alone. Abnormal colonic transit (24), vis-
ceral hypersensitivity (25), psychological factors including stress,
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FIGURE 2 | An illustrated summary of normal defecation and physiological disruptions that underlie fecal incontinence and dyssynergic defecation.
EAS, external anal sphincter; IAS, internal anal sphincter; PR, puborectalis muscle.
anxiety, and depression (26), and small intestinal bacterial over-
growth (SIBO) (27) have all been implicated with IBS-C but recent
evidence indicates that serotonin dysregulation is probably the key.
Both FC and IBS-C exhibit elevated levels of 5-hydroxytryptamine
(5-HT) in the mucosa and reduced concentrations of platelet-
depleted plasma (PDP) 5-HT after meals (28, 29). It has been
shown by Shekhar et al. that patients with IBS-C tend to be at the
sensitive end and FC at the insensitive end of the visceral sensitivity
following meal (30).
GENERAL MANAGEMENT OF CONSTIPATION
Underlying secondary causes of constipation should be evaluated
and treated first. Besides endoscopy and blood tests, exclusion of
organic disorders may require specialized tests that include high-
resolution or high-definition anorectal manometry, 3D-endoanal
ultrasound, pelvic MRI, colonic manometry, and electrophysio-
logical tests. Drugs that may cause constipation should be looked
for and stopped. Generous amount of fluids (between 1.5 and
2.0 L/day), fiber intake (25 g/day), and exercise to improve gut
transit are general advice commonly given to patients but evi-
dence are lacking (31, 32) (Table 1). Laxatives are frequently
prescribed by physicians and many patients can buy them over-
the-counter. Examples of laxatives include bulking agents (e.g.,
psyllium), stool softeners (e.g., docusate), stimulants (e.g., senna),
osmotic laxatives (e.g., polyethylene glycol), and enemas (e.g.,
phosphate). There are no firm recommendations on the use of
laxatives in most guidelines largely due to their lack of effi-
cacy and safety concerns (33) (Table 1). Polyethylene glycol
is perhaps the exception having good data on its efficacy and
safety (33).
NEW DRUGS IN THE TOOLBOX FOR THE MANAGEMENT OF
CONSTIPATION
Prokinetics (e.g., prucalopride) and secretagogues (e.g., lubipros-
tone, linaclotide) are new agents that can restore colonic function
in constipation (Table 1). Prokinetics are 5-HT4 agonists that
accelerate colonic transit time and also gastric emptying time. An
earlier version of 5-HT4 agonist, tegaserod, was shown to be effec-
tive in clinical trials (34), but the drug had been withdrawn from
the market due to its coronary and cerebrovascular side effects.
Safer drugs including mosapride (35) and renzapride (36) are in
the pipeline but highly selective 5-HT4 agonist, prucalopride, has
been shown in clinical trials to be effective and with little adverse
events (37). Available as 2 or 4 mg qd, prucalopride is approved
for use in Europe and Asia but not in the US. Velusetrag and
naronapride are other high selective 5-HT4 agonists (37).
By promoting intestinal secretion, secretagogues produce softer
stools but also accelerate intestinal transit. Lubiprostone acts on
the type 2 chloride channels (CIC-2) that leads to active secre-
tion of chloride into the luminal tract and it has been shown
to improve small bowel and colonic transit time, however, gas-
tric emptying appears to be delayed (38, 39). Given as 24µg bid
for 3 weeks, lubiprostone (Amitiza®; Sucampo Pharmaceuticals,
Bethesda, MA, USA) has been shown in a number of random-
ized controlled trials (RCTs) to be effective in improving bowel
movement, stool consistency, and also reduced bloating (33, 40).
Linaclotide, another secretagogue, has a different mechanism of
action where it acts on the guanylate cyclase-C (GC-C) that
leads to a rise in the cyclic guanosine monophosphate and subse-
quently chloride and bicarbonate secretion into the lumen (41,42).
Similarly, a number of RCTs have proven the efficacy and safety
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Table 1 | Evidence-based management of constipation.
Treatment modalities Prescription Level of evidence
Fluids 1.5–2.0 L/day Level III, grade C
Dietary fiber 25 g/day Level II, grade B
Psyllium
(e.g., Metamucil)
5.1 g bid/day Level II, grade B
Methylcellulose
(e.g., Celevac, Citrucel)
1.5–3 g bid/day Level III, grade C
Lactulose
(e.g., Duphalac,
Enulose)
10–20g/15–30 mL/day Level II, grade B
Polyethylene glycol
(e.g., Miralax)
17 g in 4–8 oz water/day Level I, grade A
Senna (e.g., Senokot) 15–25 mg/day Level III, grade C
Bisacodyl
(e.g., Dulcolax)
5–15 mg/day Level III, grade C
Prucalopride
(e.g., Resolor)
2–4 mg qd/day Level I, grade A
Lubiprostone
(e.g., Amitiza)
24µg bid/day Level I, grade A
Linaclotide
(e.g., Linzess)
145–290µg qd/day Level I, grade A
Antibiotics
(e.g., neomycin)
500 mg bid for 10 days Level II, grade B
Probiotics Strain-specific Level II, grade A (IBS)
Level III, grade C (FC)
Biofeedback therapy Six 2-weekly sessions Level I, grade A
Surgery Colectomy± ileostomy
or ileorectal anastomosis
Level II, grade B
Neuromodulation
therapy
Temporary followed by
permanent implant of
sacral nerve stimulator
Level II, grade B
Level I: good evidence-consistent results from well-designed, well-conducted tri-
als. Level II: fair evidence-results show benefit, but strength is limited by the
number, quality, or consistency of the individual studies. Level III: poor evidence-
insufficient because of limited number or power of studies, and flaws in their
design or conduct. Grade A: good evidence in support of the use of a treatment
modality, Grade B: moderate evidence in support of the use of a treatment modal-
ity, Grade C: poor evidence to support a recommendation for or against the use
of the modality, Grade D: moderate evidence against the use of the modality,
and Grade E: good evidence to support a recommendation against the use of a
modality. IBS, irritable bowel syndrome; FC, functional constipation.
of linaclotide (Linzess®; Ironwood Pharmaceuticals, Cambridge,
MA, USA) given as 145 or 290µg qd for 12 weeks (43). Linaclotide
is currently approved in the US and Europe but lubiprostone is
only approved in the US.
MANAGEMENT OF DIFFICULT AND REFRACTORY CONSTIPATION
Biofeedback is the treatment of choice for DD as shown in clinical
trials (44, 45) (Table 1). It involves neuromuscular conditioning to
improve rectoanal coordination and sensory training to improve
stool awareness and rectal compliance. On average, four to six ses-
sions are needed with an interval of 2 weeks, with each session
lasting approximately an hour (46). With completion of train-
ing, periodic reinforcements are needed to sustain its efficacy over
long-term. A trained and experienced staff and highly motivated
patient are crucial to the success for this form of therapy. If present,
SIBO especially methane-producing bacteria should be treated
with antibiotics (18, 47). There may be a role for probiotics as
part of the treatment paradigm especially in IBS (48, 49). There
is also evidence that intestinal transit time in constipated patients
can be reduced with probiotics (50). The benefits for probiotics
are at most modest and many experts agree that probiotics do not
have a firm recommendation in the management of constipation
as yet (51, 52).
Patients with slow-transit constipation due to an underlying
neuropathy are often refractory to any form of medical therapy
and surgery should be considered in such case (53, 54). Colec-
tomy and ileostomy or ileorectal anastomosis is usually required
except in certain cases of segmental involvement especially among
children (55, 56). Surgery will not improve abdominal pain or
dyssynergia and may develop diarrhea and or FI following the
operation (57). In selected patients, neuromodulation therapy or
sacral nerve stimulation (SNS) has emerged as an alternative to
surgery (Table 1). It requires a temporary placement of percuta-
neous lead to assess for any treatment response before permanent
implantation. A recent meta-analysis has shown that initial eval-
uation was successful in 42–100% of patients with constipation
and in those who had permanent SNS, 87% of patients achieved
successful improvement in symptoms, quality of life, and satisfac-
tion scores (58). Mechanisms underlying the success of SNS are
still unclear.
FECAL INCONTINENCE
PATHOPHYSIOLOGY
Fecal incontinence is a multi-factorial disorder and some of the
risk factors have included obstetric trauma (59, 60), anal trauma
or surgery (61), pelvic radiotherapy for cancer (62), smoking (60,
63), obesity (63), diabetes (64), and also certain neurological con-
ditions (65). The greater prevalence among females is attributed
to maternal injuries sustained during childbirth and in late-onset
FI, is due to changes in the pelvic floor from menopause, aging,
and pudendal neuropathy (11, 66). Moreover, aging females tend
to have lower anal resting pressure and shorter balloon expulsion
time (22) (Figure 2). Hormones can also influence the strength
and vigor of pelvic muscles (67, 68).
Besides external and internal anal sphincters, puborectalis also
plays an important role in the control of continence (69) and
injuries to these muscles and the supplying nerves, often in com-
binations, will result in FI. Unrecognized progressive neuropathy
may explain why most women who sustained an obstetrical trauma
in their 20s or 30s present with FI only in their 50s. Several stud-
ies have shown that neuropathic injury is a recognized cause for
FI (70–72) and this is especially so among women with sphincter
defects (73). There has been little progress in techniques to investi-
gate for possible neuropathy other than needle electromyography
(EMG) and pudendal nerve terminal latency (PNTL) introduced
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three decades ago. Both have significant limitations that prevent
widespread clinical use (74). Most importantly, the involvement
of spino-rectal and spino-anal pathway cannot be evaluated in a
comprehensive manner with either EMG or PNTL. Recently, the
availability of magnetic stimulation of the peripheral spinal roots
may change this paradigm (65, 75).
Rectal compliance and sensation may also affect continence
(Figure 2). A loss of rectal compliance will allow small volume of
stool to generate high intra-rectal pressure and thereby overwhelm
the anal resistance (76). This is made worst if the anorectal sen-
sation is also impaired leading to excessive accumulation of stool
(77). DD may also allow fecal seepage (78) especially in the elderly
or children with fecal impaction.
GENERAL MANAGEMENT OF FI
As with approach to constipation, secondary causes of FI should
be evaluated and treated. Those with mild symptoms may respond
to dietary modifications, medications, and exercises. Avoidance of
food triggers including caffeine, citrus fruits, spicy foods, alcohol,
or dairy products in those with intolerance may help but evidence
is lacking (7) (Table 2). Opinions also differ with regards to the
role of dietary fiber even though there is some suggestions that
methylcellulose may be better tolerated (79). Antidiarrhoeal agents
including loperamide and diphenoxylate can provide short-term
relief (80). Drugs that can enhance the sphincter tone, for exam-
ple phenylepinephrine and sodium valproate may be useful in the
passive form of FI (80). More recently, clonidine, an alpha-2 ago-
nist, was shown to improve FI in a pilot study (63) but subsequent
RCT failed to show any benefits (81).
PELVIC FLOOR EXERCISE, BIOFEEDBACK, AND TRANSCUTANEOUS
ELECTRICAL STIMULATION THERAPY
Pelvic floor muscle training or anal sphincter exercise can re-train
the striated muscles, i.e., external anal sphincter and puborectalis
but there is no consensus on the best regimen. It can be a single
regimen for all patients, e.g., 10 squeezes of 5 s each 5 times/day
or it can be individualized. Exercise can also be combined with
biofeedback therapy which has been shown to be twice as effective
as exercise alone in a study (82) (Table 2). There are considerable
variations in protocols across different centers but to be success-
ful, emphasis is the same, i.e., education, practice, motivation,
and good patient–therapist interaction. Long-term follow-up at
12 months suggests a continued response and a lower fecal incon-
tinence severity index (FISI) scores among the biofeedback-treated
patients (83). Transcutaneous electrical stimulation, either alone
or in combination with biofeedback, has been shown to be useful
(82) but the numbers are relatively small and further studies are
needed.
MINIMAL OR LESS INVASIVE TREATMENTS
In those FI patients previously failing conservative therapy, surgery
is the last option until recently when minimal or less invasive treat-
ments are available. These include injectable bulking agents, neu-
romodulation therapy in the form of permanent implant of sacral
nerve stimulator, and radiofrequency anal sphincter remodeling
(SECCA procedure) (Table 2; Figure 3).
Bulking agents are biomaterial that can be injected into the
submucosa of the anal canal to augment the anal sphincter and
Table 2 | Evidence-based management of fecal incontinence.
Treatment modalities Prescription Level of evidence
Dietary modifications Avoidance of food triggers
(e.g., caffeine, citrus fruits,
spicy foods, alcohol etc.)
Level III, grade C
Methylcellulose
(e.g., Citrucel)
1–2 Tablespoon/day Level II, grade A
Antidiarrheal agents Loperamide 4–16 mg/day
and diphenoxylate and
atropine 2.5 mg/25µg
every 3–4 h
Level II, grade C
Drugs enhancing anal
sphincter tone
Phenylepinephrine gel
10–30%, sodium valproate
400 mg qd
Level II, grade C
Clonidine 0.1 mg bid/day Level III, grade C
Pelvic floor exercise Single or individualized
regimen
Level III, grade C
Biofeedback
therapy±exercise
Six 2-weekly sessions Level II, grade B
Electrical stimula-
tion±biofeedback
–
Injectable bulking agent
(e.g., NASHA-Dx)
Solesta 1 mL injection at
four quadrants 5 mm
above dentate line
Level I, grade B
Radiofrequency anal
sphincter remodeling
(SECCA procedure)
Thermal lesion via needles
at four quadrants 2 and
1.5 cm above and below
the dentate line
Level II, grade B
Surgery or invasive
procedures
Anal sphincteroplasty,
graciloplasty or dynamic
graciloplasty, artificial
bowel sphincter, magnetic
anal sphincter
Level II, grade C
Level I: good evidence-consistent results from well-designed, well-conducted tri-
als. Level II: fair evidence-results show benefit, but strength is limited by the
number, quality, or consistency of the individual studies. Level III: poor evidence-
insufficient because of limited number or power of studies, and flaws in their
design or conduct. Grade A: good evidence in support of the use of a treatment
modality, Grade B: moderate evidence in support of the use of a treatment modal-
ity, Grade C: poor evidence to support a recommendation for or against the use
of the modality, Grade D: moderate evidence against the use of the modality,
and Grade E: good evidence to support a recommendation against the use of a
modality. IBS, irritable bowel syndrome; FC, functional constipation.
hence preserves continence. A number of different biomaterials,
for example autologous fat, Teflon, bovine glutaraldehyde cross-
linked collagen, porcine dermal collagen, dextranomer micros-
pheres in non-animal stabilized hyaluronic acid (NASHA-Dx), etc.
have been tried but with variable results. Among them, NASHA-
Dx has been evaluated extensively for its efficacy and safety in RCTs
(84,85). It was shown to be more effective than sham injection with
good tolerability and safety (85). Long-term data at 24-month have
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FIGURE 3 | An illustration of less or minimally invasive procedures
[(A) injectable bulking agent, (B) sacral nerve stimulation, and
(C) radiofrequency anal sphincter remodeling or SECCA procedure]
and invasive surgical procedures [(D) dynamic graciloplasty,
(E) artificial bowel sphincter, and (F) magnetic anal sphincter] used
in the management of fecal incontinence.
been reported to be efficacious, safe, and durable with significant
improvement in incontinence scores and quality of life scores (86).
The pre-filled NASHA-Dx injection (for example, Solesta®; Salix
Pharmaceuticals, Raleigh, USA) at four quadrants 5 mm above
the dentate line with 1 mL each can be given as outpatient without
anesthesia. A single re-treatment can be offered to patients having
persistent FI after a month.
In 1995, Matzel et al. first reported the successful use of SNS in
patients with FI and without sphincter defects (87). In a recent
meta-analysis, it was shown that SNS, compared to conserva-
tive management, significantly improved the weekly incontinence
episodes with minimal complication rates of 15% (88). A suc-
cessful outcome of therapy is typically reported as 50% reduction
of incontinence episodes from baseline. Besides being effective,
short-term and longer term outcome at 5 years for SNS have
been reported to be 42.6% based on intention-to-treat analy-
sis (89). Sphincter defects does not contradict the placement of
SNS despite initial concerns although complicated pelvic floor
disorders (including rectal resections, pelvic radiotherapy, spinal
lesions, double incontinence, and anal sphincter atrophy) are less
likely to respond. The mechanisms that underlie the success of SNS
are not entirely clear but may involve improvement in sphinc-
ter pressure (88), rectal sensitivity (90), modulation of colonic
motility (91), or alterations in corticoanal excitability (92, 93).
The SECCA procedure (Mederi Therapeutics Inc., Norwalk,
USA) delivers temperature-controlled radiofrequency energy to
the anorectal junction resulting in tissue damage, remodeling,
scarring, and contraction in order to narrow the anal canal (94).
So far, data on its efficacy have been variable and at best modest
since most patients continued to have moderate FI (95, 96).
SURGERY AND OTHER INVASIVE PROCEDURES
This is the last resort after failure of conservative and less invasive
approach but recent systematic review appears to be inconclusive
on the efficacy of surgical options in FI. If all else fails, colostomy
is considered to be the very final option. Some of the surgical tech-
niques described in literatures have included anal sphincteroplasty,
graciloplasty, artificial bowel sphincter, and magnetic anal sphinc-
ter devices (Table 2; Figure 3). Of these, anal sphincteroplasty,
which repairs or creates a new functional sphincter fashioned
from adjacent skeletal muscles, has disappointing results in clinical
studies including long-term outcome (97–100). Graciloplasty uti-
lizes the gracilis muscle to form a new sphincter and may have an
electrical stimulator implanted in the abdominal wall (dynamic
graciloplasty) to maintain the sphincter tone (101). The success
has been variable and only a few reports are available (102–104).
Artificial bowel sphincter is an inflatable cuff that acts as a sphinc-
ter and it can be deflated when the patient desires to defecate.
Again, the success has been variable from reported studies and it
is associated with high complication rates that eventually require
removal of the device (105–107). Magnetic anal sphincter involves
placement of interlinked titanium beads having internal magnetic
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cores that encircles the external anal sphincter (108). To date, the
efficacy data of this procedure appear promising (109–111) but
more studies are needed before it will see wider clinical use.
CONCLUSION
Both constipation and FI are common gastrointestinal complaints
having multi-factorial origins. Commonly affecting elderly and
women, these disorders are associated with significant impairment
in quality of life and high healthcare costs. Availability of new tech-
nologies and molecular techniques allow a better understanding
of their underlying pathophysiology that may involve any levels
along the gut–brain–microbiota axis. Many patients with mild
symptoms of constipation and FI may respond to conservative
approach that consists of diet modifications, exercise, biofeedback
therapy, and medications. More refractory cases of constipation
would require neuromodulation therapy and surgery. Likewise,
in refractory FI, less invasive approach can be tried first includ-
ing injectable bulking agents, SNS, and SECCA before moving
on to more invasive surgical approach that includes graciloplasty,
artificial bowel sphincter, or magnetic anal sphincter.
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